Characteristics of the New Coronavirus Named SARS-CoV-2 Responsible for an Infection Called Coronavirus Disease 2019 (COVID-19)

References (57)

1. 1 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [DOI]
2. 2 Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China [DOI]
3. 3 Pathological findings of COVID-19 associated with acute respiratory distress syndrome [DOI]
4. 4 A novel coronavirus outbreak of global health concern [DOI]
5. 5 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [DOI]
6. 6 World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19) [DOI]
7. 7 The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application [DOI]
8. 8 The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak [DOI]
9. 9 Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases [DOI]
10. 10 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [DOI]
11. 11 The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status [DOI]
12. 12 Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records [DOI]
13. 13 Coronaviruses: An Overview of Their Replication and Pathogenesis [DOI]
14. 14 Features, Evaluation and Treatment Coronavirus (COVID-19)
15. 15 Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR [DOI]
16. 16 The reproductive number of COVID-19 is higher compared to SARS coronavirus [DOI]
17. 17 COVID-19 and Italy: what next? [DOI]
18. 18 COVID-19 and the cardiovascular system [DOI]
19. 19 Compassionate Use of Remdesivir for Patients with Severe Covid-19 [DOI]
20. 20 Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection [DOI]
21. 21 Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies [DOI]
22. 22 Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series [DOI]
23. 23 Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine [DOI]
24. 24 Viral load of SARS-CoV-2 in clinical samples [DOI]
25. 25 Clinical Characteristics of 24 Asymptomatic Infections with COVID-19 Screened Among Close Contacts in Nanjing, China [DOI]
26. 26 Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review [DOI]
27. 27 The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China [DOI]
28. 28 Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths [DOI]
29. 29 Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease [DOI]
30. 30 Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China [DOI]
31. 31 The epidemiology and clinical information about COVID-19 [DOI]
32. 32 Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy [DOI]
33. 33 Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks [DOI]
34. 34 Coronavirus (COVID-19) outbreak: what the department of endoscopy should know [DOI]
35. 35 The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future [DOI]
36. 36 COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese–Western Medicine for the Management of 2019 Novel Coronavirus Disease [DOI]
37. 37 The COVID-19 outbreak and psychiatric hospitals in China: managing challenges through mental health service reform [DOI]
38. 38 COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? [DOI]
39. 39 Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia [DOI]
40. 40 From SARS-CoV to Coronavirus Disease 2019 (COVID-19) - A Brief Review [DOI]
41. 41 COVID-19 Outbreak and Perspective in Morocco [DOI]
42. 42 Role of integrase inhibitors in the treatment of HIV disease [DOI]
43. 43 The Proceedings of the National Academy of Sciences [DOI]
44. 44 The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China [DOI]
45. 45 Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 [DOI]
46. 46 The Coronavirus Disease 2019 (COVID-19) [DOI]
47. 47 Chloroquine and hydroxychloroquine in covid-19 [DOI]
48. 48 Controversies About COVID-19 and Anticancer Treatment with Immune Checkpoint Inhibitors [DOI]
49. 49 COVID-19: Perspectives on the Potential Novel Global Threat [DOI]
50. 50 WITHDRAWN:Experience on radiological examinations and infection prevention for COVID-19 in radiology department [DOI]
51. 51 Effective treatment of severe COVID-19 patients with tocilizumab [DOI]
52. 52 A fully automatic deep learning system for COVID-19 diagnostic and prognostic analysis [DOI]
53. 53 History of coronary heart disease increased the mortality rate of patients with COVID-19: a nested case–control study [DOI]
54. 54 International Journal of Antimicrobial Agents [DOI]
55. 55 Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine [DOI]
56. 56 Analysis of Whole Genome Sequences and Homology Modelling of a 3C Like Peptidase and a Non-Structural Protein of the Novel Coronavirus COVID-19 Shows Protein Ligand Interaction with an Aza-Peptide and a Noncovalent Lead Inhibitor with Possible Antiviral Properties [DOI]
57. 57 Analysis of Whole Genome Sequences and Homology Modelling of a 3-C Like Peptidase and a Non-Structural Protein of the Novel Coronavirus COVID-19 Shows Protein Ligand Interaction with an Aza-Peptide and a Noncovalent Lead Inhibitor with Possible Antiviral Properties [DOI]

Cited by 3

Showing 2 of 3 known citations — external sources report more than can currently be individually listed.

Related research

• Epidemiological Analysis of Infective Endocarditis at the Gold Coast Area Health Service, Australia — shares topic coverage
• Analysis of Patients Who Died Following Hartmann’s Procedure — shares topic coverage
• Is Caesarean Delivery Safe? Experience from a Low Resource Setting — shares topic coverage
• Acute Kidney Injury in Hospitalised Medical Patients: Aetiology and Prognosis — shares topic coverage
• Gender-Related Differences and Mortality Predictors among Egyptian Hemodialysis Patients: A Multi-Center Prospective Observational Study — shares topic coverage